Anika Therapeutics (NASDAQ:ANIK) Given Equal Weight Rating at Stephens

Stephens reaffirmed their equal weight rating on shares of Anika Therapeutics (NASDAQ:ANIK) in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has a $22.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also commented on ANIK. StockNews.com upgraded shares of Anika Therapeutics from a hold rating to a buy rating in a report on Thursday. Barrington Research lifted their target price on Anika Therapeutics from $29.00 to $37.00 and gave the stock an outperform rating in a report on Thursday.

Anika Therapeutics Stock Performance

Shares of Anika Therapeutics stock traded down $0.17 on Thursday, hitting $25.27. The stock had a trading volume of 104,218 shares, compared to its average volume of 85,755. The stock has a 50 day moving average of $24.15 and a 200 day moving average of $21.59. The firm has a market capitalization of $369.95 million, a P/E ratio of -4.47 and a beta of 0.75. Anika Therapeutics has a twelve month low of $16.54 and a twelve month high of $29.25.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its stake in Anika Therapeutics by 61.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,601 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 608 shares in the last quarter. Altshuler Shaham Ltd purchased a new position in shares of Anika Therapeutics in the fourth quarter valued at $58,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Anika Therapeutics by 216.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,393 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 2,320 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Anika Therapeutics during the 3rd quarter valued at $84,000. Finally, Quantbot Technologies LP purchased a new stake in Anika Therapeutics during the 3rd quarter worth about $97,000. Institutional investors own 90.79% of the company’s stock.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally.